This Research Topic highlights some of the presentations from the 3rd HAWK Consensus Conference that was held September 18-21, 2016, in Gargnano, Italy. Conference sessions covered different aspects of treating patients with C1 Inhibitor Hereditary Angioedema, specifically: may C1 inhibitor deficiency or its treatment change the risk of developing pathologic conditions; clinical markers of disease severity in patients with C1-INH-HAE; laboratory markers of disease severity in patients with C1-INH-HAE; pharmacoeconomics of C1-INH-HAE; disease modifying strategies in C1-INH-HAE; minimizing adverse events related to therapies; and establishing a network of reference centers for C1-INH-HAE.
Conference participants discussed rearrangements of the systems controlled by C1-INH to compensate it deficiency, laboratory targets that could define disease severity, and merging sustainable therapies into disease related suffering. In addition, presenters addressed concerns related to potential adverse effects of new therapies and examined the requirements for reference centers and corresponding network. Following the conference, presenters were invited to contribute to this Research Topic articles that focus on these topics.
This Research Topic highlights some of the presentations from the 3rd HAWK Consensus Conference that was held September 18-21, 2016, in Gargnano, Italy. Conference sessions covered different aspects of treating patients with C1 Inhibitor Hereditary Angioedema, specifically: may C1 inhibitor deficiency or its treatment change the risk of developing pathologic conditions; clinical markers of disease severity in patients with C1-INH-HAE; laboratory markers of disease severity in patients with C1-INH-HAE; pharmacoeconomics of C1-INH-HAE; disease modifying strategies in C1-INH-HAE; minimizing adverse events related to therapies; and establishing a network of reference centers for C1-INH-HAE.
Conference participants discussed rearrangements of the systems controlled by C1-INH to compensate it deficiency, laboratory targets that could define disease severity, and merging sustainable therapies into disease related suffering. In addition, presenters addressed concerns related to potential adverse effects of new therapies and examined the requirements for reference centers and corresponding network. Following the conference, presenters were invited to contribute to this Research Topic articles that focus on these topics.